| 书目名称 | Drug Discovery in Japan | | 副标题 | Investigating the So | | 编辑 | Sadao Nagaoka | | 视频video | | | 概述 | Provides detailed accounts of drug discoveries in Japan, from statins to Opdivo, not well understood outside Japan.Explains that science is often incomplete when discovery starts, requiring sustained | | 图书封面 |  | | 描述 | .This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery starts when the underlying science is incomplete. Thus, there exist dynamic interactions between scientific progress and drug discovery. High uncertainty also makes the value of an entrepreneurial scientist high. Such scientists fill the knowledge gaps by absorbing external scientific progress and by relentless pursuit of possibilities through their own research, often including unauthorized research, to overcome crises. Further, high uncertainty and its resolution significantly characterize the evolution of competition in the drug industry. The patent system promotes innovation under high uncertaint | | 出版日期 | Book 2019 | | 关键词 | Drug discovery; breakthrough; uncertainty; delegated initiative; competition; Statin; Opdivo | | 版次 | 1 | | doi | https://doi.org/10.1007/978-981-13-8906-1 | | isbn_softcover | 978-981-13-8908-5 | | isbn_ebook | 978-981-13-8906-1 | | copyright | Springer Nature Singapore Pte Ltd. 2019 |
The information of publication is updating
|
|
发表于 2025-3-21 16:25:01
